Loading...
Market
Which region in the US will have the highest adoption rate of Susvimo eye implant by the end of 2024?
2
Resolution / Starting Odds
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
Genentech regional sales data and market analysis reports
Story
Genentech, Roche Unit, Reintroduces Susvimo Eye Implant After Recall
Jul 8, 2024, 07:24 PM
Genentech, a unit of Roche Group, has announced the reintroduction of its eye implant, Susvimo, in the United States. The implant is designed for people with wet age-related macular degeneration (AMD), a blinding eye disease. The re-launch follows the end of a voluntary recall that took place two years ago. Susvimo, which was recalled, is a refillable implant, and it will be available to patients in the coming weeks. The announcement was made on Monday.
View original story
Similar markets
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Northeast • 25%
South • 25%
Midwest • 25%
West • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
West Coast • 25%
Northeast • 25%
Midwest • 25%
South • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other Regions • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Asia • 25%
South America • 25%
Australia • 25%